Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Holds Virtual KOL Event on Bladder Cancer Market Research

Neutral Impact 2 of 5 other Written later

enGene Therapeutics hosted a virtual key opinion leader event on August 11, 2026, to present emerging non-muscle invasive bladder cancer market research, with the slide presentation filed as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms, so it provides market context rather than a change in the company's financial position.

Key points

  • Event held August 11, 2026; presentation filed as Exhibit 99.1 to the 8-K
  • Presentation cites over 65 urologist and uro-oncologist interviews and over 2,000 NMIBC patient claims as research inputs
  • Company states its lead drug candidate detalimogene has $285 million in cash and expects 12-month pivotal cohort data and a BLA filing in 2H 2026

The filing

CompanyenGene Therapeutics Inc. (ENGN)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:03 PM ET
Accession number0001193125-26-344559

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.